Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Hepatitis C virus (HCV) infection often causes liver diseases, including fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Liver fibrosis is the outcome of the wound healing response to tissue damage caused by chronic HCV infection. This process is characterized by the excessive accumulation of extracellular matrix (ECM) proteins, such as collagen fibers secreted by activated hepatic stellate cells (HSCs). Activation of HSCs from the quiescent stage is mediated by different mechanisms, including pro-inflammatory cytokines and chemokines released from HCV-infected hepatocytes and liver macrophages. HCV infection modulates the expression of different microRNAs that can be transported and delivered to the HSCs via exosomes released from infected cells, also leading to the development of advanced disease pathogenesis. Although recent advancements in direct-acting antiviral (DAA) treatment can efficiently control viremia, there are very few treatment strategies available that can be effective at preventing pathogenesis in advanced liver fibrosis or cirrhosis in patients. Assessment of fibrosis is considered to be the major part of proper patient care and decision making in clinical practice. In this review, we highlighted the current knowledge of molecular mechanisms responsible for the progression of liver fibrosis in chronically HCV-infected patients, and currently available methods for evaluation of fibrosis in patients. A detailed understanding of these aspects at the molecular level may contribute to the development of new therapies targeting HCV-related liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475 · cited 4×
“Inflammasome is a multiprotein cytoplasmic complex that senses viral pathogen-associated molecular patterns (PAMPs) through NOD-like receptors (NLRs), especially the NLR family pyrin domain containing 3 (NLRP3) [20].”
BackgroundInfluentialExosomes: composition, biogenesis and function
Théry, C., Zitvogel, L., & Amigorena, S. (2002) · Nature Reviews Immunology · doi:10.1038/nri855 · Cited by 5,346 · cited 1×
“Exosomes are small extracellular vesicles (EVs) that are 30–100 nm in diameter, secreted by most of the cells via the exocytic pathway and are found in local and circulating body fluids [59,60].”
BackgroundThe ENCODE Project Consortium (2007) · Nature · doi:10.1038/nature05874 · Cited by 5,223
Inflammatory responses and inflammation-associated diseases in organs
Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., Li, Y., Wang, X., & Zhao, L. (2018) · Oncotarget · doi:10.18632/oncotarget.23208 · Cited by 5,143 · cited 1×
“Inflammation is a protective physiological process of the liver against most viral infections and tissue damage [14].”
BackgroundWai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Evolution and Functions of Long Noncoding RNAs
Ponting, C. P., Oliver, P. L., & Reik, W. (2009) · Cell · doi:10.1016/j.cell.2009.02.006 · Cited by 4,208
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909 · cited 1×
“Fibrosis is a consequence of wound-healing response, and is a continuous process of regeneration of damaged tissues by maintaining a balance between fibrogenesis and fibrolysis [3,4].”
BackgroundMechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Vallet-Pichard, A., Mallet, V., Nalpas, B., Verkarre, V., Nalpas, A., Dhalluin-Venier, V., Fontaine, H., & Pol, S. (2007) · Hepatology · doi:10.1002/hep.21669 · Cited by 2,077
Bravo, A. A., Sheth, S. G., & Chopra, S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440706 · Cited by 2,041
Yuan, J.-H., Yang, F., Wang, F., Ma, J.-Z., Guo, Y.-J., Tao, Q.-F., Liu, F., Pan, W., Wang, T.-T., Zhou, C.-C., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.010 · Cited by 1,515
van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J.-F., Lammert, F., Duarte-Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.144878 · Cited by 1,510
Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis
Friedrich–Rust, M., Ong, M., Martens, S., Sarrazin, C., Bojunga, J., Zeuzem, S., & Herrmann, E. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.034 · Cited by 1,490 · cited 1×
“Although it is a simple and efficient tool for detecting fibrosis, studies indicate that this technique should be used in association with other non-invasive biomarkers in HCV-infected patients [80,81].”
MethodRipoll, C., Groszmann, R., Garcia–Tsao, G., Grace, N., Burroughs, A., Planas, R., Escorsell, A., Garcia–Pagan, J. C., Makuch, R., Patch, D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.024 · Cited by 1,183
Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., Ling, M., & Albrecht, J. (2002) · Gastroenterology · doi:10.1053/gast.2002.33023 · Cited by 1,146
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model
Forns, X. (2002) · Hepatology · doi:10.1016/s0270-9139(02)00107-6 · Cited by 1,125
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents
Kanwal, F., Kramer, J., Asch, S. M., Chayanupatkul, M., Cao, Y., & El-Serag, H. B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.012 · Cited by 931 · cited 1×
“Although current treatment options such as direct-acting antivirals (DAAs) can efficiently remove viruses from human bodies in more than 95% cases, HCV elimination does not signify a liver disease cure, particularly in patients with advanced fibrosis or cirrhosis [12,13].”
BackgroundSofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Foster, G. R., Afdhal, N., Roberts, S. K., Bräu, N., Gane, E. J., Pianko, S., Lawitz, E., Thompson, A., Shiffman, M. L., Cooper, C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1512612 · Cited by 846 · cited 1×
“Fortunately for HCV genotype 3 infected patients, a second generation of DAAs with excellent SVR rates has already been introduced [89].”
BackgroundExosomes and other extracellular vesicles in host–pathogen interactions
Schorey, J. S., Cheng, Y., Singh, P. P., & Smith, V. L. (2015) · EMBO reports · doi:10.15252/embr.201439363 · Cited by 727 · cited 2×
“Exosomes are small extracellular vesicles (EVs) that are 30–100 nm in diameter, secreted by most of the cells via the exocytic pathway and are found in local and circulating body fluids [59,60].”
BackgroundInflammasome activation and IL-1β and IL-18 processing during infection
van de Veerdonk, F. L., Netea, M. G., Dinarello, C. A., & Joosten, L. A. B. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.01.003 · Cited by 691 · cited 1×
“IL-1β and IL-18 are two major cytokines produced by inflammasome-mediated pathways [21].”
BackgroundVeldt, B. J., Heathcote, E. J., Wedemeyer, H., Reichen, J., Hofmann, W. P., Zeuzem, S., Manns, M. P., Hansen, B. E., Schalm, S. W., & Janssen, H. L. A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-10-200711200-00003 · Cited by 602
Evolving challenges in hepatic fibrosis
Friedman, S. L. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.97 · Cited by 581 · cited 1×
“A key determinant of fibrosis reversion in patients with HCV is associated with clearance of activated HSCs through apoptosis [7,10].”
BackgroundExosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells
Ramakrishnaiah, V., Thumann, C., Fofana, I., Habersetzer, F., Pan, Q., de Ruiter, P. E., Willemsen, R., Demmers, J. A. A., Stalin Raj, V., Jenster, G., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221899110 · Cited by 502
Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implications
Friedman, S. L. (2004) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0055 · Cited by 498 · cited 2×
“However, prolonged liver injury results in the increased thickening of septae due to enhanced cross-linking by tissue transglutaminases and resistance to proteolysis by metalloproteinases limiting the complete regression of fibrosis [7].”
BackgroundNegash, A. A., Ramos, H. J., Crochet, N., Lau, D. T. Y., Doehle, B., Papic, N., Delker, D. A., Jo, J., Bertoletti, A., Hagedorn, C. H., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003330 · Cited by 414 · cited 2×
“Exposure to macrophages (including Kupffer cells) by circulating HCV induce inflammasome formation [17,19], although the mechanism is not fully understood.”
BackgroundCheung, M. C. M., Walker, A. J., Hudson, B. E., Verma, S., McLauchlan, J., Mutimer, D. J., Brown, A., Gelson, W. T. H., MacDonald, D. C., Agarwal, K., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.019 · Cited by 408
Progression of fibrosis in chronic hepatitis C
Ghany, M. G., Kleiner, D. E., Alter, H., Doo, E., Khokar, F., Promrat, K., Herion, D., Park, Y., Liang, T. J., & Hoofnagle, J. H. (2003) · Gastroenterology · doi:10.1053/gast.2003.50018 · Cited by 403
Giannini, E., Risso, D., Botta, F., Chiarbonello, B., Fasoli, A., Malfatti, F., Romagnoli, P., Testa, E., Ceppa, P., & Testa, R. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.2.218 · Cited by 377
Chou, R., & Wasson, N. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00005 · Cited by 370
From non-A, non-B hepatitis to hepatitis C virus cure
Pawlotsky, J.-M., Feld, J. J., Zeuzem, S., & Hoofnagle, J. H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.006 · Cited by 328 · cited 1×
“However, due to the adverse side-effects of these treatments on patient quality of life, well-tolerated combinations of direct-acting antivirals (DAAs) have largely replaced interferon (IFN)-based therapy in later stages [87,88].”
BackgroundNon-Invasive markers for hepatic fibrosis
Baranova, A., Lal, P., Birerdinc, A., & Younossi, Z. M. (2011) · BMC Gastroenterology · doi:10.1186/1471-230x-11-91 · Cited by 297 · cited 1×
“Direct biomarkers include the metabolic products of ECM, including collagen fibers, hyaluronic acid (HA), YKL-40, laminin, fibronectin, metalloproteinases (MMPs), tissue inhibitors of matrix metalloproteinases (TIMPs) and transforming growth factor-β1 (TGF-β1), which have been produced during the remodeling of ECM via…”
BackgroundJi, J., Zhang, J., Huang, G., Qian, J., Wang, X., & Mei, S. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.01.034 · Cited by 293 · cited 1×
“Downregulation of these two miRs in fully activated HSCs has resulted in restoration of the ability of quiescent HSCs, including increased accumulation of cytoplasmic lipid droplets and decreased HSC proliferation in vitro [37].”
BackgroundSimmons, B., Saleem, J., Heath, K., Cooke, G. S., & Hill, A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ396 · Cited by 261
Chronic hepatitis C and liver fibrosis
Sebastiani, G. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i32.11033 · Cited by 233 · cited 1×
“Direct biomarkers include the metabolic products of ECM, including collagen fibers, hyaluronic acid (HA), YKL-40, laminin, fibronectin, metalloproteinases (MMPs), tissue inhibitors of matrix metalloproteinases (TIMPs) and transforming growth factor-β1 (TGF-β1), which have been produced during the remodeling of ECM via…”
BackgroundMarquez, R. T., Bandyopadhyay, S., Wendlandt, E. B., Keck, K., Hoffer, B. A., Icardi, M. S., Christensen, R. N., Schmidt, W. N., & McCaffrey, A. P. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.126 · Cited by 223 · cited 1×
“miR-21 expression levels positively correlated with the fibrosis stages in CHC patients as well as a carbon tetrachloride (CCL4)-induced mouse fibrosis model [46].”
BackgroundVenugopal, S. K., Jiang, J., Kim, T.-H., Li, Y., Wang, S.-S., Torok, N. J., Wu, J., & Zern, M. A. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00220.2009 · Cited by 217 · cited 1×
“miR-150 and miR-194 are also downregulated in primary HSCs isolated from bile duct ligated rats [36].”
BackgroundLin, W., Tsai, W., Shao, R., Wu, G., Peng, L. F., Barlow, L. L., Chung, W. J., Zhang, L., Zhao, H., Jang, J., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.008 · Cited by 193 · cited 1×
“1 cells, which in turn activate HSCs [27,28].”
Devhare, P. B., Sasaki, R., Shrivastava, S., Di Bisceglie, A. M., Ray, R., & Ray, R. B. (2017) · Journal of Virology · doi:10.1128/jvi.02225-16 · Cited by 182 · cited 2×
“via the STAT3 mediated TGF-β signaling pathway [65].”
BackgroundSelf-citationWorld Health Organization. Fact sheet.
McHugh, L. B. (2000) · PubMed · Cited by 182
Reversion of disease manifestations after HCV eradication
van der Meer, A. J., & Berenguer, M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.039 · Cited by 178
Bandyopadhyay, S., Friedman, R. C., Marquez, R. T., Keck, K., Kong, B., Icardi, M. S., Brown, K. E., Burge, C. B., Schmidt, W. N., Wang, Y., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir186 · Cited by 162 · cited 1×
“Overexpression of miR-29 in LX2 cells results in proliferation reduction and suppression of collagen fiber expression [38].”
BackgroundHepatitis C Virus-Replicating Hepatocytes Induce Fibrogenic Activation of Hepatic Stellate Cells
Schulze-Krebs, A., Preimel, D., Popov, Y. V., Bartenschlager, R. F. W., Lohmann, V., Pinzani, M., & Schuppan, D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.089 · Cited by 162 · cited 1×
“An increased expression of transforming growth factor (TGF)-β1, a potent profibrogenic cytokine from HCV replicon cells, induces fibrogenesis-related gene expression for HSCs [22].”
BackgroundCardoso, A., Carvalho‐Filho, R. J., Stern, C., Dipumpo, A., Giuily, N., Ripault, M., Asselah, T., Boyer, N., Lada, O., Castelnau, C., et al. (2012) · Liver International · doi:10.1111/j.1478-3231.2011.02660.x · Cited by 149 · cited 1×
“Although it is a simple and efficient tool for detecting fibrosis, studies indicate that this technique should be used in association with other non-invasive biomarkers in HCV-infected patients [80,81].”
MethodKnockdown of Autophagy Inhibits Infectious Hepatitis C Virus Release by the Exosomal Pathway
Shrivastava, S., Devhare, P., Sujijantarat, N., Steele, R., Kwon, Y.-C., Ray, R., & Ray, R. B. (2016) · Journal of Virology · doi:10.1128/jvi.02383-15 · Cited by 140
Self-citationHepatitis C Virus Induces Interleukin-1β (IL-1β)/IL-18 in Circulatory and Resident Liver Macrophages
Shrivastava, S., Mukherjee, A., Ray, R., & Ray, R. B. (2013) · Journal of Virology · doi:10.1128/jvi.01962-13 · Cited by 136
Self-citationTzur, G., Israel, A., Levy, A., Benjamin, H., Meiri, E., Shufaro, Y., Meir, K. S., Khvalevsky, E. Z., Spector, Y., Rojansky, N., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007511 · Cited by 131 · cited 1×
“Downregulation of let-7 correlates with the activation of HSCs by targeting the TGF-β pathway in CHC patients [31,35].”
BackgroundPathogenesis of Accelerated Fibrosis in HIV/HCV Co-infection
Lin, W., Weinberg, E. M., & Chung, R. T. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis926 · Cited by 119 · cited 1×
“ROS-mediated liver injury plays an important role in cascade of liver fibrosis [26].”
BackgroundLin, W., Wu, G., Li, S., Weinberg, E. M., Kumthip, K., Peng, L. F., Méndez-Navarro, J., Chen, W., Jilg, N., Zhao, H., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.168286 · Cited by 116 · cited 1×
“1 cells, which in turn activate HSCs [27,28].”
BackgroundExtracellular vesicles: Novel mediator for cell to cell communications in liver pathogenesis
Devhare, P. B., & Ray, R. B. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.001 · Cited by 114 · cited 2×
“Exosomes originate from the multivesicular endosome (MVE) and release from cells through fusion of MVEs to the plasma membrane [61].”
BackgroundSelf-citationShrivastava, S., Petrone, J., Steele, R., Lauer, G. M., Bisceglie, A. M. D., & Ray, R. B. (2013) · Hepatology · doi:10.1002/hep.26296 · Cited by 111 · cited 1×
“We observed a significant upregulation of miR-20a expression in the serum of HCV-infected liver fibrosis patients, with gradual increase from the early stage to the late stage of fibrosis, which may serve as a predictive biomarker of liver fibrosis detection in the early stage [30].”
BackgroundSelf-citationGiugliano, S., Kriss, M., Golden-Mason, L., Dobrinskikh, E., Stone, A. E. L., Soto-Gutierrez, A., Mitchell, A., Khetani, S. R., Yamane, D., Stoddard, M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.040 · Cited by 108
Matsuura, K., Giorgi, V. D., Schechterly, C. A., Wang, R. Y., Farci, P., Tanaka, Y., & Alter, H. J. (2016) · Hepatology · doi:10.1002/hep.28660 · Cited by 105 · cited 1×
“Downregulation of let-7 correlates with the activation of HSCs by targeting the TGF-β pathway in CHC patients [31,35].”
BackgroundInflammasome: A Double-Edged Sword in Liver Diseases
Luan, J., & Ju, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02201 · Cited by 100 · cited 1×
“We have further shown HCV-induced cancer stem-like cells (CSCs) when implanted into immune-deficient mice activate stromal fibroblasts [25].”
BackgroundKarsdal, M. A., Krarup, H., Sand, J. M. B., Christensen, P. B., Gerstoft, J., Leeming, D. J., Weis, N., Schaffalitzky de Muckadell, O. B., & Krag, A. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12820 · Cited by 95 · cited 2×
“HCV-related liver fibrosis initiates a wide range of disease progressions in patients along with the alteration of normal architecture and function of the liver [68].”
BackgroundIntegrative miRNA and Gene Expression Profiling Analysis of Human Quiescent Hepatic Stellate Cells
Coll, M., Taghdouini, A. E., Perea, L., Mannaerts, I., Vila-Casadesús, M., Blaya, D., Rodrigo-Torres, D., Affò, S., Morales-Ibanez, O., Graupera, I., et al. (2015) · Scientific Reports · doi:10.1038/srep11549 · Cited by 91 · cited 1×
“Differential expression of miRs has been reported in HCV-induced liver fibrosis and is involved in HSC activation [33,34].”
BackgroundKim, J. H., Lee, C. H., & Lee, S. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.006 · Cited by 91 · cited 2×
“Upregul t d miR-192 in HCV infection is ra sported to HSCs via ex somes to induce th activation of HSCs and the production f fibrogenic markers [67].”
BackgroundHepatitis C virus–induced CCL5 secretion from macrophages activates hepatic stellate cells
Sasaki, R., Devhare, P. B., Steele, R., Ray, R., & Ray, R. B. (2017) · Hepatology · doi:10.1002/hep.29170 · Cited by 79 · cited 2×
“Interestingly, IL-1β does not involve activation of HSCs [23].”
BackgroundSelf-citationmiR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan
Halász, T., Horváth, G., Pár, G., Werling, K., Kiss, A., Schaff, Z., & Lendvai, G. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i25.7814 · Cited by 79 · cited 1×
“miR-122, the most abundant microRNA in the liver, was found to be negatively associated with fibrosis in HCV-infected patients [43,44].”
BackgroundMicroRNA-17-5p-activated Wnt/β-catenin pathway contributes to the progression of liver fibrosis
Yu, F., Lu, Z., Huang, K., Wang, X., Xu, Z., Chen, B., Dong, P., & Zheng, J. (2016) · Oncotarget · doi:10.18632/oncotarget.6447 · Cited by 78
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?
Calvaruso, V., & Craxì, A. (2013) · Liver International · doi:10.1111/liv.12395 · Cited by 77
Long non-coding RNA GAS5 inhibited hepatitis C virus replication by binding viral NS3 protein
Qian, X., Xu, C., Zhao, P., & Qi, Z. (2016) · Virology · doi:10.1016/j.virol.2016.02.020 · Cited by 72
Sarma, N. J., Tiriveedhi, V., Subramanian, V., Shenoy, S., Crippin, J. S., Chapman, W. C., & Mohanakumar, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050826 · Cited by 70 · cited 1×
“Downregulation of miR-449a also plays an important role in the modulation of YKL40 expression, a factor known to induce the synthesis of extracellular matrix and fibrosis through targeting the NOTCH signaling pathway components in HCV-infected patients [40].”
BackgroundSarma, N. J., Tiriveedhi, V., Crippin, J. S., Chapman, W. C., & Mohanakumar, T. (2014) · Journal of Virology · doi:10.1128/jvi.03060-13 · Cited by 66 · cited 1×
“The HCV-induced downregulation of miR-449a and miR-107 correlates with increased CCL2 (a major inflammatory chemokine) and STAT3 phosphorylation expression by targeting components of the interleukin-6 receptor (IL-6R) complex, such as IL-6R and JAK1, respectively, in infected patients resulting in hepatic fibrosis [39…”
BackgroundFu, N., Zhao, S., Kong, L.-B., Du, J., Ren, W., Han, F., Zhang, Q., Li, W., Cui, P., Wang, R., et al. (2017) · Gene · doi:10.1016/j.gene.2017.03.008 · Cited by 56 · cited 1×
“The involvement of TGFβ-induced lncRNA-ATB in HCV-associated liver fibrosis is suggested by modulating the expression of miR-200a [57].”
BackgroundRamachandran, S., Basha, H. I., Sarma, N. J., Lin, Y., Crippin, J. S., Chapman, W. C., & Mohanakumar, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070744 · Cited by 55 · cited 1×
“Upregulated miR-200c in HCV- infected patients regulates the Src-kinase signaling pathway by directly targeting FAS-associated phosphatase 1 (FAP-1), a negative regulator of Src signaling, thus promoting hepatic fibrosis [48].”
BackgroundExpression of novel long noncoding RNAs defines virus-specific effector and memory CD8+ T cells
Hudson, W. H., Prokhnevska, N., Gensheimer, J., Akondy, R. S., McGuire, D. J., Ahmed, R., & Kissick, H. T. (2019) · Nature Communications · doi:10.1038/s41467-018-07956-7 · Cited by 53
MicroRNA-mediated interactions between host and hepatitis C virus
Li, H., Jiang, J.-D., & Peng, Z.-G. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i4.1487 · Cited by 49
Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges
Ekpanyapong, S., & Reddy, K. R. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619840149 · Cited by 48 · cited 3×
“At this stage, fibrosis becomes more adverse and progresses towards liver cirrhosis (LC) [3,9].”
BackgroundFu, N., Niu, X., Wang, Y., Du, H., Wang, B., Du, J., Li, Y., Wang, R., Zhang, Y., Zhao, S., et al. (2016) · PubMed · Cited by 47
Improving performance of liver biopsy in fibrosis assessment
Asselah, T., Marcellin, P., & Bédossa, P. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.03.006 · Cited by 47 · cited 3×
“There are several semi-quantitative scoring systems such as METAVIR, Knodell and Ishak that are available for diagnosing l v r fibrosis, and these are used in clinical pr ctice [70].”
BackgroundMethodAbdel-Al, A., El-Ahwany, E. G., Zoheiry, M. K., Hassan, M. N. M., Ouf, A. A., Abu-Taleb, H. M., Rahim, A. A., El-Talkawy, M. D., & Zada, S. K. (2018) · Virus Research · doi:10.1016/j.virusres.2018.06.007 · Cited by 47 · cited 1×
“A study using an Egyptian patient cohort indicated that miR-16, miR-146a, miR-221 and miR-222 can be used as effective biomarkers for HCV-induced fibrosis, since these miRs are upregulated in early and late fibrosis, and miR-222 and miR-221 are important for their high sensitivity and specificity in late-stage fibrosi…”
MethodWang, Y., Rao, H., Chi, X., Li, B., Liu, H., Wu, L., Zhang, H., Liu, S., Zhou, G., Li, N., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.07.043 · Cited by 46 · cited 1×
“0% of the DAA-based group and was more frequent in patients with genotype 3 [97].”
BackgroundShaker, O. G., & Senousy, M. A. (2017) · Journal of Viral Hepatitis · doi:10.1111/jvh.12696 · Cited by 43 · cited 1×
“Differentially expressed serum miRs are considered important non-invasive biomarkers for different stages of HCV-associated liver fibrosis progression in patients [41].”
BackgroundSasaki, R., Devhare, P. B., Ray, R. B., & RAY, R. K. (2017) · Hepatology · doi:10.1002/hep.29346 · Cited by 42 · cited 1×
“NLRP3 also plays an important role in HSC activation and involves pro-inflammatory cytokine production, resulting in inflammation-induced liver fibrosis [24].”
BackgroundSelf-citationNon-Coding RNAs and Hepatitis C Virus-Induced Hepatocellular Carcinoma
Plissonnier, M., Herzog, K., Levrero, M., & Zeisel, M. B. (2018) · Viruses · doi:10.3390/v10110591 · Cited by 39
Cytokinome profile evaluation in patients with hepatitis C virus infection.
Capone, F., Guerriero, E., Colonna, G., Maio, P., Mangia, A., Castello, G., & Costantini, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i28.9261 · Cited by 38 · cited 1×
“Chronic HCV infection is positively associated with increased expression of different pro-inflammatory cytokines and chemokines from hepatocytes, liver residential macrophages (Kupffer cells) and different immune cells (macrophages, natural killer cells and dendritic cells) recruited to the liver [17,18].”
BackgroundKim, J. H., Lee, C. H., & Lee, S. (2016) · The Journal of Microbiology · doi:10.1007/s12275-016-6240-3 · Cited by 32
Sur, S., Sasaki, R., Devhare, P. B., Steele, R., Ray, R., & Ray, R. B. (2018) · Journal of Virology · doi:10.1128/jvi.01215-18 · Cited by 30
Self-citationChronic Hepatitis C: Conspectus of immunological events in the course of fibrosis evolution
Baskić, D., Vukovic, V. R., Popović, S., Jovanović, D., Mitrović, S., Djurdjevic, P. M., Avramovic, D., Arsovic, A., Banković, D., Čukić, J., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219508 · Cited by 29
Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis
Jaroszewicz, J., Flisiak‐Jackiewicz, M., Lebensztejn, D. M., & Flisiak, R. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1057568 · Cited by 26 · cited 2×
“At this stage, fibrosis becomes more adverse and progresses towards liver cirrhosis (LC) [3,9].”
BackgroundLong Non-coding RNAs in Hepatitis C Virus-Infected Cells
Barriocanal, M., & Fortes, P. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01833 · Cited by 24
Long-Term Impact of Direct-Acting Antiviral Agent Therapy in HCV Cirrhosis: Critical Review
Fehily, S. R., Papaluca, T., & Thompson, A. J. V. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1685538 · Cited by 23 · cited 1×
“Therefore, DAAs are recommended for use in all patients with significant liver fibrosis or cirrhosis, including decompensated cirrhosis [93].”
BackgroundHepatitis C Virus Manipulates Humans as its Favorite Host for a Long‐Term Relationship
Ray, R. B., & Ray, R. (2018) · Hepatology · doi:10.1002/hep.30214 · Cited by 22 · cited 1×
“Based on the variations of genomic sequences, HCV is classified into seven genotypes and different subtypes, among which genotypes 1, 2 and 3 are more predominant than the others [1].”
BackgroundSelf-citationMechanisms involved in liver damage resolution after hepatitis C virus clearance
SALAS-VILLALOBOS, T. B., Lozano-Sepúlveda, S. A., Rincón‐Sánchez, A. R., Govea‐Salas, M., & Rivas, A. (2017) · Medicina Universitaria · doi:10.1016/j.rmu.2017.05.005 · Cited by 20 · cited 1×
“Fibrosis is a dynamic process and may reverse upon resolution of HCV infection at an early stage [8].”
BackgroundPentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C
Górka-Dynysiewicz, J., Pazgan−Simon, M., & Zuwała−Jagiełło, J. (2019) · BioMed Research International · doi:10.1155/2019/2639248 · Cited by 18 · cited 1×
“The levels of PTX3 are significantly higher in patients with advanced fibrosis compared to the F0–F1 stage, and significantly correlate with other indirect serum biomarkers as well as with the histological stage of liver fibrosis in HCV patients [82].”
BackgroundKhanizadeh, S., Ravanshad, M., Hosseini, S. Y., Davoodian, P., Zadeh, A. N., Sabahi, F., Sarvari, J., Khanlari, Z., & Hassaniazad, M. (2016) · Acta Virologica · doi:10.4149/av_2016_03_242 · Cited by 14 · cited 2×
“Transfection of protease-competent or protease-mutants from the HCV NS3 genomic region into HSCs downregulates the expression of miR-122 in HSCs during fibrosis [44].”
BackgroundBaskić, D., Vukovic, V. R., Popović, S., Jovanović, D., Mitrović, S., Djurdjevic, P. M., Avramovic, D., Arsovic, A., Banković, D., Čukić, J., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221142 · Cited by 11
NS5A: A new target for antiviral drugs in the treatment of hepatitis C virus infection
Debes, J. D., & Smith, C. I. (2012) · Hepatology · doi:10.1002/hep.25696 · Cited by 7 · cited 1×
“However, due to the adverse side-effects of these treatments on patient quality of life, well-tolerated combinations of direct-acting antivirals (DAAs) have largely replaced interferon (IFN)-based therapy in later stages [87,88].”
Background
Cited by
Roles and mechanisms of exosomal non-coding RNAs in human health and diseases
Li, C., Ni, Y.-Q., Xu, H., Xiang, Q.-Y., Zhao, Y., Zhan, J.-K., He, J.-Y., Li, S., & Liu, Y.-S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00779-x · Cited by 406
Computational analysis of microRNA-mediated interactions in SARS-CoV-2 infection
Saçar Demirci, M. D., & Adan, A. (2020) · PeerJ · doi:10.7717/peerj.9369 · Cited by 190
“…in host-virus interaction might provide a deeper understanding for viral pathogenesis and the development of an effective antiviral therapy as shown in several viruses including Herpesvirus, Enterovirus and Hepatitis C (Piedade & Azevedo-Pereira, 2016; Engelmann et al., 2018; Khatun & Ray, 2019).”
BackgroundHeterogeneity of HSCs in a Mouse Model of NASH
Rosenthal, S. B., Liu, X., Ganguly, S., Dhar, D., Pasillas, M. P., Ricciardelli, E., Li, R. Z., Troutman, T. D., Kisseleva, T., Glass, C. K., et al. (2021) · Hepatology · doi:10.1002/hep.31743 · Cited by 145
Metadata
- Authors
- Khatun, M., & Ray, R. B.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-10-14
- Volume
- 8
- Issue
- 10
- Pages
- 1249
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W2979590060
- Cited by
- 187
- References
- 90
- FWCI
- 14.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.